Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AgomAb Therapeutics NV stock logo
AGMB
AgomAb Therapeutics
$5.44
-3.2%
$8.85
$5.39
▼
$17.82
$197.15MN/A155,227 shs179,665 shs
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
$7.43
-2.2%
$11.86
$5.50
▼
$17.96
$214.16M2.62629,437 shs601,197 shs
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
$7.92
-2.7%
$9.33
$7.72
▼
$14.39
$286.06M0.26148,867 shs268,683 shs
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
$0.38
-0.9%
$0.56
$0.30
▼
$1.63
$77.84M1.192.37 million shs2.08 million shs
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AgomAb Therapeutics NV stock logo
AGMB
AgomAb Therapeutics
-3.44%-11.64%-35.62%-57.58%+561,999,900.00%
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
-5.47%-9.95%-30.78%-43.49%+25.83%
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
-1.57%-10.45%-9.96%-39.61%-37.86%
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
-4.34%-6.32%+10.83%-59.56%-61.76%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AgomAb Therapeutics NV stock logo
AGMB
AgomAb Therapeutics
$5.44
-3.2%
$8.85
$5.39
▼
$17.82
$197.15MN/A155,227 shs179,665 shs
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
$7.43
-2.2%
$11.86
$5.50
▼
$17.96
$214.16M2.62629,437 shs601,197 shs
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
$7.92
-2.7%
$9.33
$7.72
▼
$14.39
$286.06M0.26148,867 shs268,683 shs
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
$0.38
-0.9%
$0.56
$0.30
▼
$1.63
$77.84M1.192.37 million shs2.08 million shs
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AgomAb Therapeutics NV stock logo
AGMB
AgomAb Therapeutics
-3.44%-11.64%-35.62%-57.58%+561,999,900.00%
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
-5.47%-9.95%-30.78%-43.49%+25.83%
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
-1.57%-10.45%-9.96%-39.61%-37.86%
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
-4.34%-6.32%+10.83%-59.56%-61.76%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AgomAb Therapeutics NV stock logo
AGMB
AgomAb Therapeutics
2.89
Moderate Buy$37.50589.34% Upside
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
3.00
Buy$24.50229.70% Upside
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
2.70
Moderate Buy$21.85175.93% Upside
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
2.60
Moderate Buy$4.19993.34% Upside

Current Analyst Ratings Breakdown

Latest LUCD, AGMB, ARCT, and BNTC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/16/2026
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
Reiterated RatingSell (E+)
11/16/2026
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
Boost Price TargetOutperform$18.00 ➝ $18.27
11/16/2026
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
Boost Price TargetOutperform$17.00 ➝ $20.00
11/12/2026
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
Reiterated RatingBuy
11/2/2026
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
Reiterated RatingBuy
10/23/2026
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
Initiated CoverageOutperform$14.00
10/23/2026
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
Reiterated RatingBuy
10/21/2026
AgomAb Therapeutics NV stock logo
AGMB
AgomAb Therapeutics
Reiterated RatingBuy
10/21/2026
AgomAb Therapeutics NV stock logo
AGMB
AgomAb Therapeutics
Reiterated RatingBuy
10/21/2026
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
UpgradeHold ➝ Strong-Buy
10/15/2026
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
Reiterated RatingSell (D-)
(Data available from 11/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AgomAb Therapeutics NV stock logo
AGMB
AgomAb Therapeutics
N/AN/AN/AN/AN/AN/A
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
$82.03M2.61N/AN/A$5.85 per share1.27
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
N/AN/AN/AN/A$4.70 per shareN/A
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
$4.71M16.53N/AN/A$0.03 per share12.77
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AgomAb Therapeutics NV stock logo
AGMB
AgomAb Therapeutics
-$70.77MN/AN/AN/AN/AN/AN/AN/AN/A
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
-$65.78M-$3.08N/AN/AN/A-285.92%-46.79%-36.50%N/A
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
-$45.55M-$1.02N/AN/AN/AN/A-27.60%-26.78%N/A
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
-$58.01M-$0.40N/AN/AN/A-892.75%N/A-142.71%N/A

Latest LUCD, AGMB, ARCT, and BNTC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/13/2026Q3 2026
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
-$0.2750-$0.26+$0.0150-$0.26N/AN/A
11/12/2026Q3 2026
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
-$0.0575-$0.06-$0.0025-$0.03$1.63 million$1.20 million
11/5/2026Q3 2026
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
-$0.6866-$0.26+$0.4266-$0.26$8.00 million$18.30 million
9/14/2026Q4 2026
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
-$0.2643-$0.26+$0.0043-$0.2590$13.70 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
AgomAb Therapeutics NV stock logo
AGMB
AgomAb Therapeutics
N/AN/AN/AN/AN/A
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
N/AN/AN/AN/AN/A
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
N/AN/AN/AN/AN/A
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AgomAb Therapeutics NV stock logo
AGMB
AgomAb Therapeutics
N/A
12.88
N/A
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
N/A
6.68
6.68
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
N/A
19.62
34.00
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
N/A
1.20
1.18

Institutional Ownership

CompanyInstitutional Ownership
AgomAb Therapeutics NV stock logo
AGMB
AgomAb Therapeutics
N/A
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
94.54%
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
52.19%
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
74.01%

Insider Ownership

CompanyInsider Ownership
AgomAb Therapeutics NV stock logo
AGMB
AgomAb Therapeutics
N/A
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
17.80%
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
7.96%
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
6.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
AgomAb Therapeutics NV stock logo
AGMB
AgomAb Therapeutics
6236.24 millionN/AN/A
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
11128.82 million23.69 millionOptionable
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
2436.12 million33.24 millionOptionable
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
82203.24 million189.22 millionNo Data

Recent News About These Companies

Lucid Diagnostics' (LUCD) "Buy" Rating Reiterated at BTIG Research
Lucid Diagnostics (LUCD) Q3 2026 Earnings Call Transcript
Lucid Diagnostics Analyst Price Targets

New MarketBeat Followers Over Time

Media Sentiment Over Time

AgomAb Therapeutics stock logo

AgomAb Therapeutics NASDAQ:AGMB

$5.44 -0.18 (-3.20%)
Closing price 03:59 PM Eastern
Extended Trading
$5.43 -0.01 (-0.18%)
As of 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

We are a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Our product candidates are designed to target established pathways and utilize validated modalities with the aim of increasing efficacy while avoiding systemic toxicities in order to overcome the limitations of prior therapeutic approaches. Our initial focus for the treatment of fibrosis is through inhibition of one of the key signaling pathways involved in fibrosis, the transforming growth factor ß, or TGFß, pathway. Our mission is to develop disease-modifying therapeutics that aim to resolve fibrosis and restore organ function to enable patients with these disorders to live fuller and healthier lives. We are advancing a pipeline of novel product candidates for chronic fibrotic disorders with well-validated targets, significant unmet medical needs and large commercial potential. Our pipeline includes: • Ontunisertib (AGMB-129): Our lead product candidate, ontunisertib, is a selective and potent oral, gastrointestinal-restricted small molecule inhibitor of ALK5, or TGFßR1, in development for the treatment of Fibrostenosing Crohn’s Disease, or FSCD. FSCD is a severe complication of Crohn’s Disease, or CD, that is associated with significant morbidity. There are approximately 1.4 million patients under treatment for CD in the seven major markets of the United States, France, Germany, Italy, Spain, the United Kingdom and Japan, and approximately 620,000, or 46%, of these patients have FSCD. The emergence of burdensome symptomatic strictures is considered to be an inevitable consequence of long-term inflammation for the large proportion of patients with CD who progress to FSCD and eventually require surgery. There are no approved pharmacologic therapies for FSCD. We believe ontunisertib has the potential to change the paradigm for treating FSCD patients and provide the first pharmacologic treatment for strictures. Ontunisertib is designed to act locally in the gastrointestinal tract, enabling high exposure in the target tissue. Then, following absorption, ontunisertib is rapidly inactivated in the liver to avoid potential toxicities associated with systemic TGFß signaling inhibition. In November 2025, we announced topline results of the global randomized, double-blind, placebo-controlled Phase 2a trial of ontunisertib, or the STENOVA trial, in 103 FSCD symptomatic patients with at least one ileal stricture. Part A of the STENOVA study achieved its primary endpoint of assessing the safety and tolerability of ontunisertib 100mg QD and 200mg BID in FSCD patients. Pharmacokinetic results confirmed the GI-restricted profile of ontunisertib, with high local and low systemic exposure of ontunisertib in FSCD patients. We also observed positive signals on several exploratory clinical endpoints. The 48-week open-label treatment extension of the STENOVA trial with ontunisertib is currently ongoing and we expect to report the results of such open-label treatment extension in the second half of 2026. Based on the positive results observed in the STENOVA study to date, we are preparing to initiate a Phase 2b trial of ontunisertib in patients with symptomatic FSCD in the second half of 2026. • AGMB-447: AGMB-447, our second clinical-stage product candidate, is an inhaled small molecule inhibitor of ALK5, or TGFßR1, in development for the treatment of idiopathic pulmonary fibrosis, or IPF. IPF is a rare progressive fibrotic lung disease that has a poor prognosis for patients with a median life expectancy of less than five years. IPF affects approximately 240,000 people in the United States, Japan, the United Kingdom, and the four largest European markets (France, Germany, Spain, and Italy), with 30,000 to 40,000 new cases being diagnosed each year in the United States alone. AGMB-447 is designed to have a high local exposure in the lung tissue, and then upon absorption into the bloodstream, AGMB-447 is hydrolyzed and substantially inactivated in order to avoid potential toxicities associated with systemic inhibition of ALK5 signaling. Direct delivery to the lung through inhalation and subsequent lung restriction are designed to confer high efficacy and a favorable safety profile for AGMB-447. We believe AGMB-447 also has the potential to demonstrate a low potential for drug-drug interactions that could make it well-suited for use as a single-agent and in combination with current standard of care therapies. We are conducting a Phase 1 trial with AGMB-447 and have enrolled 108 healthy participants in the SAD and MAD B1-B6 portions of the trial, initiated the IPF cohort and enrolled the first patients. We completed an interim analysis of the SAD and MAD B1-6 stages in 108 healthy participants, where we observed positive topline interim results, and expect to report data from IPF patients in the second half of 2026. • Discovery and preclinical portfolio: We have a robust discovery pipeline including several programs in the early stages of development. Fibrosis and the role of TGFß Fibrosis represents an aberrant response of a tissue to injury, leading to progressive tissue scarring that may be triggered by trauma, inflammation, infection, cell injury or cancer, amongst others. As a result, fibrosis can lead to organ dysfunction and failure. The body’s normal response to injury involves the activation of cells that produce collagen and other components of the extracellular matrix, or ECM, that are part of the healing process for the tissue. Under normal physiological circumstances, scarring is self-limited and the resulting scar resolves itself, leaving behind a tissue architecture similar to what was present before the injury. However, in certain chronic disease states, this process of healing becomes both prolonged and excessive, resulting in fibrotic remodeling which interferes with organ function. Fibrosis can occur in many organ systems throughout the body including the lungs, liver, kidneys, gastrointestinal tract, skin and muscles. While the exact pathologies for diseases in these organs differ, fibrosis involves many of the same cell types and signaling pathways across different organs and tissue. Signaling by TGFß has been shown to play a central role in the pathophysiology of fibrosis. The well understood role of the TGFß pathway, including through the ALK5 receptor, in driving multiple aspects of fibrosis, has made it an attractive target for antifibrotic drug development. In healthy tissue, TGFß’s physiological role is to initiate healing after injury. In fibrotic diseases, however, TGFß signaling remains continuously activated in response to prolonged insults such as inflammation, leading the surrounding tissue to deposit excess ECM, which eventually leads to tissue fibrosis. There is strong preclinical evidence and encouraging preliminary clinical evidence that TGFß inhibition could be effective in multiple indications; however, development of previous ALK5 inhibitors has been limited due to safety concerns as systemic inhibition of TGFß causes toxicity in the heart and large vessels. We believe our programs have the potential to overcome these systemic toxicity challenges by acting locally within tissue of interest and avoiding systemic exposure while allowing us to leverage the well-described role of TGFß in fibrosis. We were initially incorporated under the laws of Belgium on April 13, 2017 as a Belgian private limited liability company (besloten vennootschap) and were converted under the laws of Belgium into a Belgian limited liability company (naamloze vennootschap) on March 14, 2019. Our principal executive offices are located in Antwerpen, Belgium.

Arcturus Therapeutics stock logo

Arcturus Therapeutics NASDAQ:ARCT

$7.43 -0.17 (-2.22%)
Closing price 03:59 PM Eastern
Extended Trading
$7.40 -0.03 (-0.35%)
As of 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Benitec Biopharma stock logo

Benitec Biopharma NASDAQ:BNTC

$7.92 -0.22 (-2.70%)
Closing price 04:00 PM Eastern
Extended Trading
$7.92 0.00 (-0.06%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

Lucid Diagnostics stock logo

Lucid Diagnostics NASDAQ:LUCD

$0.38 0.00 (-0.85%)
Closing price 03:58 PM Eastern
Extended Trading
$0.38 -0.01 (-1.31%)
As of 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.